Although myc and bcl-2 synergize in tumor development, particularly lymphomagenesis, it is not known whether endogenous bcl-2 is required for mycinduced tumorigenesis. To investigate the role of endogenous Bcl-2 in myc-induced lymphomagenesis, we bypassed the early death of Bcl-2-deficient mice by reconstituting lethally irradiated wild-type (wt) mice with a hematopoietic system from fetal liver-derived stem cells of E-myc/ bcl-2 ؊/؊ or control E-myc transgenic embryos. In premalignant (healthy) recipients, loss of Bcl-2 caused a moderate decrease in pre-B and immature B cells, and a dramatic reduction of mature B lymphocytes expressing the E-myc transgene. Furthermore, cultured preneoplastic E-myc/bcl-2 ؊/؊ mature B cells displayed accelerated apoptosis compared with E-myc B cells. However, despite the striking reduction in B-cell numbers in vivo, ablation of endogenous Bcl-2 did not prevent or even delay development of E-myc lymphoma. Moribund mice presented with similar degrees of splenomegaly, blood leukocyte numbers, and tumor dissemination at death. These findings demonstrate that the initiation, development, continued growth, and severity of E-myc lymphoma do not depend upon endogenous Bcl-2, nor upon the total number of B lymphoid cells driven by the E-myc transgene. 
Introduction
Activation of the c-myc proto-oncogene by the t(8;14) chromosomal translocation is the key transforming event in the etiology of human Burkitt lymphoma, and deregulated myc expression also features in numerous other human cancers, including cervical and small-cell lung carcinoma and myeloid leukemia. 1 The transcriptional regulator c-Myc drives diverse cellular processes, including cell volume growth, cell-cycle progression, inhibition of differentiation, and, when growth factors are limiting, apoptotic cell death. 2 Apoptosis (programmed cell death) is a genetically controlled process for killing unwanted cells that is essential for the normal development and function of multicellular organisms. 3 Abnormalities in cell death control can also promote tumorigenesis. 4 The first cell death regulator to be discovered was the bcl-2 gene, which was identified by its frequent translocation in human follicular B-cell lymphoma. 5 Its oncogenic potential was revealed when Bcl-2 overexpression was shown to promote the survival (but not proliferation) of pro-B cells deprived of cytokine. 6 Experiments using transgenic mice have provided considerable insight into the complexities of neoplastic transformation. Deregulated c-myc expression under the control of the immunoglobulin heavy chain (IgH) gene enhancer (E) causes abnormal growth and proliferation of pre-B and B cells and impedes differentiation, culminating in clonal pre-B or immature B-cell lymphoma. [7] [8] [9] The stochastic nature of tumor onset in these animals indicates that malignant transformation requires secondary genetic aberrations, such as inactivation of the ARF-Mdm2-p53 pathway, 10 loss of proapoptotic BH3-only proteins Bim 11 or Puma, 12 or deregulated expression of Bcl-2-like prosurvival proteins. [13] [14] [15] These changes are believed to counter the proapoptotic action of Myc under suboptimal growth conditions. 4 Increased cell survival on its own is not a strong impetus for tumorigenesis. Transgenic mice expressing Bcl2 under control of the IgH gene enhancer, mimicking the t(14;18) translocation found in follicular-center B lymphoma, have a 3-to 5-fold increase in B cells, 16, 17 yet only approximately 5% develop lymphoma within the first year of life. 18 Bcl-2 appears to promote tumorigenesis by allowing cells to survive while acquiring additional oncogenic mutations, such as a c-myc translocation. Indeed, E-myc/E-bcl-2 bitransgenic mice succumb to lymphoma more rapidly (100% mortality by 7 weeks of age) than those bearing only the E-myc transgene (less than 40% mortality at this time), 13 and progression of human follicular lymphoma from an indolent to a more aggressive state is often associated with acquisition of a c-myc translocation. 19, 20 Recent work has established that sustained Bcl-2 overexpression is required for the continued growth of lymphomas evoked by the deregulated expression of both Myc and Bcl-2. 21 This observation supports the view that Bcl-2 will be an important target for treating those tumors arising from enforced Bcl-2 expression. 22 However, most cancers, including hematopoietic neoplasms, do not harbor bcl-2 gene translocations or amplifications, and the current thrust to develop Bcl-2 antagonists highlights the need to determine whether endogenous bcl-2 is required for the initiation and sustained growth of cancers. It also The online version of this article contains a data supplement.
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remains unclear whether the inhibition of apoptosis is critical in the selection of an initiating cell or is required only later in tumor progression. Since Bcl-2 is expressed in many lymphoid cell subsets, including early progenitors, 23, 24 and because Bcl-2 overexpression enhances the survival of B lymphocytes at all stages of development, 16, 17, 25 endogenous Bcl-2 levels may be a crucial determinant of E-myc-induced lymphomagenesis.
Here, we have addressed these issues by investigating the role of endogenous Bcl-2 in Myc-induced growth, proliferation, survival, and transformation of B lymphoid cells. To overcome the complication that young Bcl-2-deficient mice, particularly those on a C57BL/6 background, succumb to polycystic kidney disease, [26] [27] [28] [29] we have studied wild-type mice whose hematopoietic system was reconstituted with either E-myc/bcl-2 Ϫ/Ϫ or, as a control, with E-myc/bcl-2 ϩ/ϩ hematopoietic stem cells. Surprisingly, despite a marked reduction of B cells in E-myc/bcl-2 Ϫ/Ϫ reconstituted mice, lymphoma onset and severity were not altered compared with control E-myc reconstituted animals.
Materials and methods

Mice and hematopoietic reconstitution
All experiments with animals were conducted according to the guidelines of the Melbourne Directorate Animal Ethics Committee. All mouse strains had been backcrossed to the C57BL/6 (Ly5.2 ϩ ) genetic background more than 10 generations prior to use in the experiments shown here. The E-myc transgenic mice 7 and bcl-2 gene targeted mice 27 have both been described previously. Polymerase chain reaction (PCR)-based genotyping for Emyc 11 and bcl-2 29 was performed as described.
Maternal transmission of the E-myc transgene has previously been demonstrated to produce a reduction in tumor latency (A. Harris and J.M.A., unpublished results, February 1988). Breeding was therefore undertaken as follows: E-myc transgenic males were first crossed with bcl-2 ϩ/Ϫ females, and their E-myc/bcl-2 ϩ/Ϫ male offspring were then mated with bcl-2 ϩ/Ϫ females. Embryos from these matings were harvested at embryonic day 14.5 (E14.5) and genotyped by PCR on tail-derived DNA. Single-cell suspensions were prepared from fetal liver, and cell viability was determined by trypan blue exclusion. Then, 2 ϫ 10 6 hematopoietic fetal liver cells were injected into the tail vein of lethally irradiated (2 ϫ 5.5 Gy in a 3-hour interval) C57BL/6-Ly5.1 ϩ mice. Mice that received transplants were maintained on neomycin sulfate-supplemented drinking water for 14 days after irradiation to prevent infection.
Reconstituted mice were monitored daily for signs of malignancy or other signs of ill health. Mice were killed when deemed moribund by an experienced animal technician who was blinded to the genotype of the cells used for hematopoietic reconstitution. Typically, the moribund mice presented with several (but not always all) of the following features: hunched posture, labored breathing, weight loss, enlarged lymph nodes (LNs) and/or spleen, peripheral white blood cell (WBC) cellularity of 20 ϫ 10 6 /mL or greater, a dominant (clonal) donor-derived (Ly5.2 ϩ ) B lymphoid (B220 ϩ and/or CD19 ϩ ) population detected by immunofluorescent staining with cell surface marker-specific antibodies and fluorescence-activated cell sorter (FACS) analysis, the ability of leukemic cells from spleen or LNs to form a tumor upon transplantation into nonirradiated histocompatible recipients, and histologic evidence of disseminated lymphoma.
Preneoplastic analysis was performed on mice 8 to 12 weeks following hematopoietic reconstitution. To confirm that these mice were free of tumors at the time of analysis, 10 6 spleen or LN cells were injected intravenously into 2 or 3 congenic recipient mice as previously described. 8, 9 Hematopoietic reconstituted mice were deemed tumor-free when all recipients autopsied 80 days after transplantation demonstrated no overt signs of malignancy.
Immunofluorescent staining, flow cytometric analysis, and cell sorting
Analysis of preleukemic cells and primary lymphomas was performed by preparing single-cell suspensions and incubating cells in 2.4G2 (antiFc␥RII) antibody (at approximately 2 mg/mL) plus 2% normal rat serum and staining with rat monoclonal antibodies to: B220 (RA3-6B2), CD19 (ID3), c-Kit (ACK2 or ACK4), IgM (5.1 or 333.12), IgD (11-26C), CD4 (H1289 or YTA321), CD8 (YTS169), Mac-1(MI/70), Gr-1 (RB6-8C5), and erythroid cell-specific marker (Ter119). Host (Ly5.1 ϩ ) and donor-derived (Ly5.2 ϩ ) cell populations were discriminated by staining with monoclonal antibodies: anti-Ly5.1 (A201.1) and anti-Ly5.2 (5.450.15.2). Antibodies were conjugated to fluorescein isothiocyanate (FITC; Molecular Probes, Eugene, OR), phycoerythrin (PE; Prozyme, San Leandro, CA), cyanine 5 (Cy5; Amersham Biosciences, Arlington Heights, IL), allophycocyanin (APC; Prozyme) or biotin (Molecular Probes) according to the manufacturers' protocols. Biotinylated antibodies were detected by secondary staining using FITC-, PE-or Tricolor-coupled streptavidin (Caltag, Carlsbad, CA). Dead cells were excluded by propidium iodide (PI) staining (2 g/mL). Purification of preleukemic donor-derived B lymphoid subpopulations was performed by multiparameter FACS sorting using a MoFlo (Cytomation, Fort Collins, CO) or DiVa (BD Biosciences, Palo Alto, CA) high-speed flow cytometer. Sorting was performed on the basis of forward (FSC) and side light scatter (SSC), by exclusion of Ly5.1 ϩ and PI ϩ cells and by the following staining: B220 ϩ c-Kit ϩ sIg Ϫ for pro-B cells, B220 ϩ c-Kit Ϫ sIg Ϫ for pre-B cells, B220 ϩ sIgM hi sIgD lo for immature B cells, and B220 ϩ sIgM lo sIgD hi for mature B cells. Absolute numbers of B lymphoid subpopulations were determined by cell counting and multiplying cell numbers by the percentage of Ly5.2 ϩ cell subsets as determined by FACS.
Cell culture and cell-survival assays
FACS-purified B lymphocyte populations were cultured at 2 to 5 ϫ 10 4 cells (per time point) in the high-glucose version of Dulbecco modified Eagle medium (DMEM) supplemented with 250 M L-asparagine, 50 M 2-mercaptoethanol, and 10% heat-inactivated fetal calf serum (JRH Biosciences, Kansas City, MO). Cell viability was determined by staining with PI (2 g/mL) and FITC-labeled Annexin V followed by analysis in a FACScan (Becton Dickinson, San Jose, CA).
Cell-cycle analysis
Purified B lymphocyte populations (10 5 cells) were washed with balanced salt solution (containing Ca 2ϩ and Mg 2ϩ ) and resuspended in 200 L of ice-cold PI staining solution (10 mM Tris (pH 8.0), 1 mM NaCl, 0.1% Nonidet P40, 50 g/mL PI, and 10 g/mL RNaseA). Samples were vortexed briefly and incubated on ice for 10 minutes. DNA content was determined by analyzing an equal number of events (10 4 cells/sample) using a FACScan (Becton Dickinson, San Jose, CA) with linear amplification settings. Percentages of cells in G 0 /G 1 and S/G 2 /M were determined by manual gating using WEASEL (Water and Eliza Hall Institute) analysis software.
Statistical analysis
Statistical significance was assessed using the Student t test, and KaplanMeier curves were constructed using Graph Pad Prism software (version 3.0; Cary, NC). Statistical evaluation of tumor-free survival data was undertaken using a log-rank test or a 1-way ANOVA test using Graph Pad Prism (version 3.0). For more information, see the Supplemental Materials, available on the Blood website (click the Supplemental Materials link at the top of the online article).
Results
Abnormally low numbers of E-myc/bcl-2 ؊/؊ leukocytes in reconstituted mice
To investigate how endogenous Bcl-2 affects myc-induced lymphomagenesis, we reconstituted lethally irradiated C57BL/6-Ly5.1 ϩ (wild-type [wt]) mice with fetal liver hematopoietic stem cells from Ly5.2 E-myc/bcl-2 Ϫ/Ϫ or, as controls, from E-myc/bcl-2 ϩ/ϩ , E-myc/bcl-2 ϩ/Ϫ , bcl-2 ϩ/Ϫ , bcl-2 Ϫ/Ϫ , and wt embryos (E14.5). Hereafter, these reconstituted animals are referred to as E-myc/ bcl-2 Ϫ/Ϫ , E-myc/bcl-2 ϩ/Ϫ , E-myc, bcl-2 Ϫ/Ϫ , bcl-2 ϩ/Ϫ , or wt mice. The efficacy of hematopoietic reconstitution was examined initially 8 to 10 weeks after transplantation by staining peripheral blood leukocytes with monoclonal antibodies to Ly5.1 (host) and Ly5.2 (donor). Mice that received transplants of E-myc, E-myc/ bcl-2 ϩ/Ϫ , bcl-2 ϩ/Ϫ , or wt cells routinely exhibited 85% or more donor-derived hematopoietic cells, whereas recipients of E-myc/ bcl-2 Ϫ/Ϫ or bcl-2 Ϫ/Ϫ cells consistently showed lower percentages (less than 70%) and overall numbers of leukocytes ( Figure 1A ). Subsequent analysis of peripheral blood at 20 weeks after transplantation revealed that while the percentages (and total numbers) of donor-derived leukocytes remained the same (or even increased) for wt or E-myc mice, those in E-myc/bcl-2 Ϫ/Ϫ and bcl-2 Ϫ/Ϫ recipients were frequently reduced even further ( Figure S1 , available on the Blood website; see the Supplemental Figures link at the top of the online article). The reduced numbers of Bcl-2-deficient leukocytes in the blood is consistent with previous evidence of attrition of bcl-2 Ϫ/Ϫ cells in peripheral lymphoid organs. 29, 30 To determine whether the lowered leukocyte cellularity of E-myc/ bcl-2 Ϫ/Ϫ and bcl-2 Ϫ/Ϫ mice reflected a decreased proportion of B cells (sIg ϩ ), we stained leukocytes from peripheral blood of E-myc/bcl-2 Ϫ/Ϫ , E-myc, bcl-2 Ϫ/Ϫ and wt mice with monoclonal antibodies to B220, IgM, IgD, and Ly5.2. Indeed, bcl-2 Ϫ/Ϫ mice contained significantly fewer donor-derived sIg ϩ B cells in their blood than their wt counterparts ( Figure 1A) . Moreover, E-myc/bcl-2 Ϫ/Ϫ mice exhibited a notable decrease (P Ͻ .05) when compared with bcl-2 Ϫ/Ϫ mice, and a profound decline (P Ͻ .005) relative to E-myc animals ( Figure 1A) .
Preneoplastic E-myc/bcl-2 ؊/؊ mice display a marked reduction in mature B cells
The reduced numbers of B cells in the blood of E-myc/bcl-2 Ϫ/Ϫ mice led us to determine the specific developmental stage at which B lymphopoiesis was perturbed in these animals. As expression of the E-myc transgene commences very early in B lineage commitment, 8 we examined B-cell development from the pro-B to the mature B-cell stage in the reconstituted mice, all of which were verified to be lymphoma-free by demonstrating that injection of 10 6 spleen or LN cells into non-irradiated C57BL/6 mice did not result in tumor formation within 80 days. We quantified pro-B (B220 ϩ or CD19 ϩ c-Kit ϩ sIg Ϫ ), pre-B (B220 ϩ or CD19 ϩ c-Kit Ϫ sIg Ϫ ), immature B (B220 ϩ or CD19 ϩ sIgM hi sIgD lo ), and mature B cells (B220 ϩ or CD19 ϩ sIgM lo sIgD hi ) in bone marrow, spleen, and LNs by immunofluorescent staining with surface marker-specific monoclonal antibodies and FACS analysis.
In the marrow (Figure 1B) , the bcl-2 Ϫ/Ϫ recipients had numbers of pro-B and pre-B cells similar to that of wt recipients; however, bcl-2 Ϫ/Ϫ reconstituted mice displayed an approximately 3-fold drop in sIg ϩ B cells (P Ͻ .05). Compared with wt recipients, the E-myc marrow had an approximately 5-fold excess of large pre-B cells and an approximately 3-fold reduction in the more differentiated sIg ϩ B cells. 8 Compared with the E-myc animals, the marrow of E-myc/bcl-2 Ϫ/Ϫ mice had similar numbers of pro-B cells, but approximately 2-to 3-fold lower numbers (P Ͻ .05) of both pre-B and sIg ϩ B cells ( Figure 1B) .
In the spleens of the recipients, flow cytometric analysis ( Figure  2A ) revealed that the E-myc/bcl-2 Ϫ/Ϫ recipients exhibited a modest decline in the proportion of immature B cells (R1 window) and a marked reduction in mature B cells (R2 window). This reduction in the percentage of mature B cells translated into a more than 10-fold reduction (P Ͻ .005) in their total number compared to that in E-myc animals ( Figure 2A) . Similarly, the LNs ( Figure  2B ) of E-myc/bcl-2 Ϫ/Ϫ mice were almost completely devoid of mature B lymphocytes (approximately 40-fold less than in E-myc mice; P Ͻ .001). Comparison of all B lymphoid subsets between E-myc and E-myc/bcl-2 ϩ/Ϫ mice revealed that loss of a single bcl-2 allele did not significantly reduce the size of any of these populations ( Figure S2 ). Taken together, these results indicate that endogenous Bcl-2 is critical for the survival of mature E-myc B cells but is less important for the maintenance of pro-B, pre-B, and immature B cells.
Loss of bcl-2 accelerates E-myc-induced apoptosis of cytokine-deprived mature B cells in culture
To determine whether the reduced numbers of mature B cells in E-myc/bcl-2 Ϫ/Ϫ mice was a reflection of increased apoptosis, we purified donor-derived (Ly5.2 ϩ ) pro-B (B220 ϩ c-Kit ϩ sIg Ϫ ), pre-B (B220 ϩ c-Kit Ϫ sIg Ϫ ), immature B (B220 ϩ sIgM hi sIgD lo ), and mature B cells (B220 ϩ sIgM lo sIgD hi ) from bone marrow or spleen by FACS sorting and monitored their survival in culture following cytokine deprivation. Upon culture in simple medium (without added growth factors), bcl-2 Ϫ/Ϫ pro-B, pre-B, and immature B cells died at comparable rates to that of control wt cells (Figure 3) . In contrast, as described Figure 1 . Impaired B lymphopoiesis in E-myc/bcl-2 ؊/؊ reconstituted mice. Analysis of total numbers of leukocytes and B lymphocyte populations in peripheral blood (A) and bone marrow (B) from lethally irradiated mice reconstituted 8 to 12 weeks earlier with wt, bcl-2 Ϫ/Ϫ , E-myc, or E-myc/bcl-2 Ϫ/Ϫ fetal liver-derived stem cells. (A) Blood leukocytes were counted in an automated blood analyzer and percentages of donorderived sIg ϩ B cells determined by staining with fluorochrome-conjugated monoclonal antibodies to B220, IgM, IgD, and Ly5.2 followed by FACS analysis. (B) Leukocytes from bone marrow (2 femurs per mouse) were counted in a hemocytometer and donor derived pro-B (Ly5.2 ϩ B220 ϩ c-Kit ϩ sIg Ϫ ), pre-B (Ly5.2 ϩ B220 ϩ c-Kit Ϫ sIg Ϫ ), and B cells (Ly5.2 ϩ B220 ϩ c-Kit Ϫ sIg ϩ ) quantified by staining with surface marker-specific monoclonal antibodies followed by FACS analysis. Data represent means Ϯ SEM from 4 to 6 mice of each genotype. Statistically significant differences: *P Ͻ .05; **P Ͻ .005.
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Deregulated myc expression enhances cytokine withdrawalinduced apoptosis of many cell types, 31 including B lymphoid cells. 32 Accordingly, E-myc B lymphoid cells at all developmental stages died more rapidly than their wt (nontransgenic) counterparts ( Figure 3) . The E-myc/bcl-2 Ϫ/Ϫ and E-myc pre-B cells died at a similar rate, whereas immature B cells of E-myc/bcl-2 Ϫ/Ϫ origin showed moderately enhanced death, most evident at the latest time point (48 hours). Notably, a significant acceleration of apoptosis (eg, at 16 hours; P Ͻ .001) was evident in E-myc/bcl-2 Ϫ/Ϫ mature B cells across all time points examined; indeed, by 24 hours, all of the E-myc/bcl-2 Ϫ/Ϫ mature B cells, yet only 55% of their E-myc counterparts had died (Figure 3 ). These observations demonstrate that endogenous Bcl-2 is critical for countering the proapoptotic effects of deregulated myc expression in mature B cells, and has a minor role in immature B cells, but appears to be dispensable for pro-B and pre-B-cell survival.
Deregulated cycling of E-myc transgenic pro-B and pre-B cells is unaffected by loss of endogenous Bcl-2
Preleukemic E-myc transgenic mice have a 4-to 5-fold expansion in cycling pro-B and pre-B cells. 8 Since lymphocytes overexpressing Bcl-2 exhibit delayed cell-cycle entry following mitogenic stimulation, [33] [34] [35] we examined whether loss of endogenous Bcl-2 affected the cycling of E-myc or nontransgenic B cells. Donorderived (Ly5.2 ϩ ) pro-B and pre-B cells purified from the bone marrow of preleukemic reconstituted animals by FACS sorting were subjected to DNA content analysis by PI staining and flow cytometry. Quantification of the cells residing in the S/G 2 /M phases revealed that loss of endogenous Bcl-2 did not affect cycling of pro-B or pre-B cells, regardless of whether or not they expressed the E-myc transgene (Figure 4) . Moreover, flow cytometric analysis of forward light scatter revealed no difference in size between E-myc and E-myc/bcl-2 Ϫ/Ϫ pro-B or pre-B cells ( Figure  S3 ). These results show that endogenous Bcl-2 is not required for the myc-induced growth or cycling of B lymphoid cells.
Loss of endogenous bcl-2 does not affect E-myc-induced lymphomagenesis
To examine the role of endogenous Bcl-2 in E-myc-induced lymphoma development, cohorts of E-myc (n ϭ 18), E-myc/ bcl-2 ϩ/Ϫ (n ϭ 27), and E-myc/bcl-2 Ϫ/Ϫ (n ϭ 26) reconstituted mice were monitored daily for general health, LN enlargement, and splenomegaly. To serve as tumor-free controls, lethally irradiated mice were also reconstituted with wt, bcl-2 ϩ/Ϫ , or bcl-2 Ϫ/Ϫ fetal liver cells, and, as expected, none of these mice developed lymphoma over the course of 18 months. As previously observed, 36, 37 tumor latency is longer in mice reconstituted with E-myc cells than in nonmanipulated E-myc transgenic animals (compare data in Figure S4 with those in Figure 5 and Figure S5 ). Nevertheless, mice reconstituted with E-myc fetal liver cells reproducibly developed lymphoma with a median onset of 49 weeks and 70% mortality by 18 months ( Figure 5 ). Remarkably, loss of both alleles of bcl-2 did not retard E-myc-induced lymphoma development, yielding a median tumor latency of 46 weeks ( Figure 5 ). Statistical analysis revealed no significant difference in tumor latency or overall mortality between these cohorts of animals ( Figure S5 ).
The predominant immunophenotype of the lymphomas arising in the E-myc/bcl-2 Ϫ/Ϫ reconstituted animals was that of pro/pre-B (B220 ϩ CD19 ϩ sIg Ϫ ), and to a lesser extent, of immature B (B220 ϩ CD19 ϩ sIgM ϩ sIgD Ϫ )-cell origin (Figure 6A-B ; Table S1 ).
Although moribund E-myc/bcl-2 Ϫ/Ϫ mice frequently presented with smaller LNs than lymphomatous E-myc and E-myc/ bcl-2 ϩ/Ϫ mice, no overall reduction in severity of lymphoma was conferred by loss of Bcl-2, as evidenced by comparable spleen size (E-myc ϭ 0.32 Ϯ 0.1 g vs E-myc/bcl-2 Ϫ/Ϫ ϭ 0.28 Ϯ 0.05 g) and similarly elevated leukocyte cellularity in the blood (Emyc ϭ 46 Ϯ 14 ϫ 10 6 /mL vs E-myc/bcl-2 Ϫ/Ϫ ϭ 39 Ϯ 21 ϫ 10 6 / mL; Figure 7A ). In addition, histologic analysis revealed similar pathology in moribund E-myc/bcl-2 Ϫ/Ϫ and E-myc mice, including extensive disruption of the normal architecture of LNs and bone marrow by large lymphoma cells and frequent lymphoma infiltration of the liver, lung, and kidney ( Figure 7B ; data not shown). Moreover, transplantation tests established that all E-myc/ bcl-2 Ϫ/Ϫ (n ϭ 8) and control E-myc (n ϭ 5) lymphomas tested were transplantable, producing lymphoma and leukemia in (nonirradiated) histocompatible recipients within 30 days.
To begin to explore whether loss of endogenous Bcl-2 had selected for development of lymphomas expressing abnormal levels of anti-or proapoptotic members of the Bcl-2 family or other apoptosis regulators, we subjected lysates from 3 E-myc/bcl-2 Ϫ/Ϫ and 3 control E-myc lymphomas to Western blot analysis. The expression levels of Bcl-x L and Mcl-1 varied among the lymphomas tested, but there was no obvious correlation with the presence or absence of endogenous Bcl-2. The proapoptotic BH3-only proteins Bim, Puma, Bad, and Bid were expressed at comparable levels in all lymphomas, as was the multi-BH domain proapoptotic Bcl-2 family member Bax, as well as Apaf-1, and caspase-1, caspase-2, caspase-6, caspase-8, and caspase-9 ( Figure S6 ). Curiously, caspase-3 was not detectable in all the tumors analyzed ( Figure S6 ), but there was no obvious difference between the E-myc and E-myc/bcl-2 Ϫ/Ϫ lymphomas, since 1 in 3 of each appeared to lack caspase-3 expression. These results suggest that the E-myc/bcl-2 Ϫ/Ϫ lymphomas appear not to have selected for any consistent abnormality in expression levels of pro-or antiapoptotic Bcl-2 family members or downstream effectors of apoptosis.
Discussion
Despite current efforts to develop Bcl-2 antagonists for antitumor therapy. 22 the contribution of endogenous bcl-2 to lymphomagenesis has not previously been investigated. Since Bcl-2 is expressed at multiple stages of B-cell development, 23, 24 and inhibition of apoptosis is considered an essential requirement for tumorigenesis, 4, 38 we reasoned that loss of endogenous bcl-2 might impair E-myc-induced B lymphomagenesis. To explore this issue, we circumvented the early postnatal lethality caused by germline Bcl-2 deficiency 26, 29 by studying lymphoma development in wt mice reconstituted with E-myc/bcl-2 Ϫ/Ϫ or E-myc/bcl-2 ϩ/ϩ (E-myc) fetal liver stem cells. This system has proven very effective for revealing how genetic changes can accelerate or delay E-mycinduced lymphomagenesis. 36, 37 Moreover, the protracted tumorfree period in these animals allowed us to determine the consequences of Bcl-2 loss on nontransformed E-myc-expressing B lymphoid cells.
Mice reconstituted with wt or bcl-2 Ϫ/Ϫ fetal liver cells had similar numbers of pro-B cells and pre-B cells in their bone marrow, and these cells died at comparable rates in culture. Similarly, premalignant E-myc/bcl-2 Ϫ/Ϫ and control E-myc mice had comparable numbers of pro-B and pre-B cells that survived equally well in culture. Bcl-2 is probably not essential for the survival of these cells because pre-B cells normally express only low levels of Bcl-2. 23, 24 This indicates that other prosurvival Bcl-2 family members, such as Bcl-x L , which is highly expressed in pre-B lymphocytes, 39 are essential for inhibiting myc-induced apoptosis in these cells. 40 Moreover, since pro-B cells express relatively high levels of Bcl-2, 23,24 their survival may be guaranteed by the redundant action of Bcl-2 and at least one of its homologs. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From Mice deficient for bcl-2 have been reported to display high levels of spontaneous lymphocyte apoptosis in vivo but, surprisingly, cell culture experiments indicated that bcl-2 Ϫ/Ϫ splenic B cells died at a rate comparable with their wt counterparts. 30 Those studies, however, were carried out with total splenic B220 ϩ cells, most of which in a bcl-2 Ϫ/Ϫ reconstituted mouse are of immature (sIgM hi sIgD lo ) B-cell origin. When we analyzed the immature (B220 ϩ sIgM hi sIgD lo ) and mature (B220 ϩ sIgM lo sIgD hi ) B cells separately, we found that loss of Bcl-2 accelerated the death of the mature B cells in culture and reduced their number in vivo much more than that of immature B cells. These observations, which held both for control (nontransgenic) B cells and those expressing the E-myc transgene, are consistent with the finding that mature B cells express high levels of Bcl-2, whereas immature B cells express only low levels. 23 Pertinently, experiments with cells from Bcl-x-deficient embryos have indicated that Bcl-x L is the prosurvival Bcl-2 family member critical for blocking apoptosis in immature sIgM hi sIgD lo B cells. 41 The reduced repopulation potential we observed with E-myc/ bcl-2 Ϫ/Ϫ fetal liver-derived stem cells, like that noted previously for Bcl-2-deficient cells, 30 probably reflects the prevalence of Bcl-2 expression in hematopoietic stem and progenitor cells. 23, 24 Nevertheless, despite the reduced reconstitution efficacy and the marked mature B-cell deficit in preleukemic E-myc/bcl-2 Ϫ/Ϫ mice, their progression to malignancy occurred with an onset and incidence similar to those observed in E-myc reconstituted control animals. The comparable lymphoma onset kinetics, taken together with the acceleration of E-myc/bcl-2 Ϫ/Ϫ mature B-cell apoptosis both in vivo and in vitro, demonstrate that the survival of the more mature B cells is not essential for E-myc-induced lymphomagenesis or sustained lymphoma growth.
These findings support the notion that a more immature cell type-one for which Bcl-2 is dispensable for survival-is the likely origin of early neoplastic clones in E-myc transgenic mice. An analogous observation has been made with preleukemic E-myc/E-max41 bitransgenic mice, which have less than 1% of the normal number of circulating peripheral blood B lymphocytes, yet develop lymphoma at a rate comparable with that of Emyc control mice. 42 Conversely, E-myc/E-bcl-2 bitransgenic animals exhibit prodigious numbers of cycling mature (sIg ϩ ) B lymphoid cells, but all the tumors that arise in these animals have a very primitive ("stem cell"-like) phenotype, and the more mature bitransgenic B cells do not elicit tumors on transplantation. 13 Taken together, these observations suggest that even though many Emyc lymphomas express surface immunoglobulin, indicative of a mature phenotype, lymphomagenesis most likely initiates in a primitive lymphoid progenitor or stem cell. It may be relevant that Burkitt lymphomas, although they have a very different cellular origin (germinal-center B cells) contain very little Bcl-2. 43 However, whether Bcl-2 was present during their development remains unknown.
Our finding that loss of endogenous Bcl-2 accelerated apoptosis of preneoplastic mature E-myc B cells, together with the demonstration that removing Bcl-2 decimated the tumors arising in E-myc/E-bcl-2 mice, 21 supports the concept that inactivating the function (or expression) of Bcl-2 and closely related prosurvival proteins will prove an important new approach to therapy. 44 Indeed, in preclinical studies, the compound ABT-737, which inactivates several Bcl-2 family members, has shown considerable promise with chronic lymphocytic leukemia as well as certain other tumors. 22 Our finding that endogenous Bcl-2 is not required for the sustained growth of E-myc lymphomas that have not arisen as a consequence of Bcl-2 overexpression indicates that targeting Bcl-2 specifically might not be effective for this class of tumor. Targeting several of the Bcl-2 homologs (eg, using ABT-737) may provide a more efficacious approach. Eventually, however, we surmise that antagonizing a critical individual prosurvival Bcl-2 family member, such as Bcl-x L , offers the best prospect for selective killing of certain types of tumor cells while minimizing damage to normal tissues. Moreover, when the inherent ability of myc overexpression to sensitize cells to apoptotic stimuli is better understood, that may also provide an attractive adjunct strategy for targeted cancer therapy.
